The overall ratings of 6 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Depomed, Inc. (DEPO) is having a tough week. The company’s rating falls from a C to a D. Depomed, Inc. develops new and proprietary oral drug delivery technologies. The company also gets F’s in operating margin growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of DEPO stock.
Paratek Pharmaceuticals Inc (PRTK) slips from a D to a F this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.
This week, Sucampo Pharmaceuticals, Inc. Class A’s (SCMP) rating worsens to a D from the company’s C rating a week ago. Sucampo Pharmaceuticals, Inc. Class A is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SCMP stock.
Zogenix, Inc.’s (ZGNX) rating weakens this week, dropping to a D versus last week’s C. Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The company also gets F’s in operating margin growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZGNX stock.
This is a rough week for Intellipharmaceutics International Inc. (IPCI). The company’s rating falls to F from the previous week’s D. Intellipharmaceutics International Inc. develops drug delivery technologies. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of IPCI stock.
This week, DURECT Corporation (DRRX) drops from a D to a F rating. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
